/

Società

Ar

Non verificato

Arcturus Therapeutics

Di cosa scriviamo

AccessoriBiotecnologiaFarmaceuticaMedicina - VarieVetrine/Shopping

2 comunicati stampa

Guarda tutti i comunicati

23/06/2025

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Eventi

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

Fonte

Arcturus Therapeutics

Emittente

1.00

0

03/09/2024

Industria

Igiene alimentare

Salute

Biotecnologia

Medicina - Varie

Farmaceutica

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Fonte

Arcturus Therapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0